No profile data available.
TuHURA Biosciences, Inc. (HURA) is a healthcare company in the additional cancer treatment drugs industry, based in Tampa, United States, with about 22 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$30.06 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $124.90 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. 0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
TuHURA Biosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$124.90 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include ALX Oncology Holdings Inc. (ALXO), Kazia Therapeutics Limited (KZIA), Inovio Pharmaceuticals, Inc. (INO), Foghorn Therapeutics Inc. (FHTX).